litlas
ログインアカウント作成

Keith D. Wilner

1990–2025 年に発表

66
論文数
29,085
被引用数
51
h 指数
64
i10 指数

被引用数

Keith D. Wilner の年別被引用数1990 年: 被引用 1 件1991 年: 被引用 4 件1992 年: 被引用 5 件1993 年: 被引用 4 件1994 年: 被引用 4 件1995 年: 被引用 3 件1996 年: 被引用 3 件1997 年: 被引用 2 件1998 年: 被引用 8 件1999 年: 被引用 7 件2000 年: 被引用 13 件2001 年: 被引用 8 件2002 年: 被引用 13 件2003 年: 被引用 14 件2004 年: 被引用 10 件2005 年: 被引用 16 件2006 年: 被引用 10 件2007 年: 被引用 13 件2008 年: 被引用 17 件2009 年: 被引用 12 件2010 年: 被引用 31 件2011 年: 被引用 187 件2012 年: 被引用 382 件2013 年: 被引用 431 件2014 年: 被引用 463 件2015 年: 被引用 570 件2016 年: 被引用 505 件2017 年: 被引用 442 件2018 年: 被引用 432 件2019 年: 被引用 1,063 件2020 年: 被引用 1,000 件2021 年: 被引用 805 件2022 年: 被引用 678 件2023 年: 被引用 457 件2024 年: 被引用 675 件2025 年: 被引用 268 件2026 年: 被引用 8 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,413 件、この内訳の 28.3%中国: 引用元論文 867 件、この内訳の 10.2%イタリア: 引用元論文 468 件、この内訳の 5.5%イギリス: 引用元論文 407 件、この内訳の 4.8%ドイツ: 引用元論文 391 件、この内訳の 4.6%フランス: 引用元論文 389 件、この内訳の 4.6%日本: 引用元論文 367 件、この内訳の 4.3%スペイン: 引用元論文 321 件、この内訳の 3.8%カナダ: 引用元論文 273 件、この内訳の 3.2%韓国: 引用元論文 263 件、この内訳の 3.1%オランダ: 引用元論文 231 件、この内訳の 2.7%スイス: 引用元論文 229 件、この内訳の 2.7%
0%28.3%その他 22.2%

機関

分野

  • Medicine76%
  • Biochemistry, Genetics and Molecular Biology18.5%
  • Pharmacology, Toxicology and Pharmaceutics1%
  • Computer Science0.8%
  • Mathematics0.7%
  • Immunology and Microbiology0.6%
  • その他2.4%

トピック

  • Lung Cancer Treatments and Mutations16.4%
  • Lung Cancer Research Studies8.2%
  • Cancer Genomics and Diagnostics5.9%
  • Lung Cancer Diagnosis and Treatment4.8%
  • Cancer Immunotherapy and Biomarkers2.6%
  • Cancer therapeutics and mechanisms2.3%
  • その他59.8%

共著者

全論文

検索で開く
  1. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

    著者: Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall - New England Journal of Medicine 2014 被引用: 3,213

  2. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    著者: Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang, D. Ross Camidge, Benjamin Solomon, Ravi Salgia, Gregory J. Riely, Marileila Varella‐Garcia, Geoffrey I. Shapiro, Daniel B. Costa, Robert C. Doebele, Long P. Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S. Martin Shreeve, L. Tye, James G. Christensen, Keith D. Wilner, Jeffrey W. Clark, A. John Iafrate - New England Journal of Medicine 2014 被引用: 1,993

  3. Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

    著者: Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne - New England Journal of Medicine 2013 被引用: 3,406

  4. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

    著者: A. Shaw, G.J. Riely, Yung‐Jue Bang, Donghyeon Kim, D.R. Camidge, Benjamin Solomon, Marileila Varella‐Garcia, A. John Iafrate, Geoffrey I. Shapiro, Tiziana Usari, Stewart C. Wang, Keith D. Wilner, Jeffrey W. Clark, S.‐H.I. Ou - Annals of Oncology 2019 被引用: 577

  5. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

    著者: Gregory J. Riely, Egbert F. Smit, Myung‐Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne S. Tsao, Melissa L. Johnson, Francesco Gelsomino, Raymond M. Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo‐Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith D. Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson - Journal of Clinical Oncology 2023 被引用: 114

  6. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

    著者: Alexander Drilon, Jeffrey W. Clark, Jared Weiss, Sai‐Hong Ignatius Ou, D. Ross Camidge, Benjamin Solomon, Gregory A. Otterson, Liza C. Villaruz, Gregory J. Riely, Rebecca S. Heist, Mark M. Awad, Geoffrey I. Shapiro, Miyako Satouchi, Toyoaki Hida, Hidetoshi Hayashi, Danielle Murphy, Sherry Wang, Sherry Li, Tiziana Usari, Keith D. Wilner, Paul K. Paik - Nature Medicine 2020 被引用: 393

  7. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    著者: Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou, Ryohei Katayama, Christine M. Lovly, Nerina T. McDonald, Pierre P. Massion, Christina T. Siwak-Tapp, Adriana González, Rong Fang, Eugene J. Mark, Julie M. Batten, Haiquan Chen, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, David P. Carbone, Hongbin Ji, Jeffrey A. Engelman, Mari Mino–Kenudson, William Pao, A. John Iafrate - Journal of Clinical Oncology 2012 被引用: 1,557

  8. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    著者: Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate - New England Journal of Medicine 2010 被引用: 4,504

  9. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

    著者: Richard S. Finn, Katalin Boér, Igor Bondarenko, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, Nataliia Voitko, Eustratios Bananis, Lynn McRoy, Keith D. Wilner, Xin Huang, Sindy Kim, Dennis J. Slamon, Johannes Ettl - Breast Cancer Research and Treatment 2020 被引用: 170

  10. Crizotinib in Patients With MET-Amplified NSCLC

    著者: D. Ross Camidge, Gregory A. Otterson, Jeffrey W. Clark, Sai‐Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I. Shapiro, Mark A. Socinski, Danielle Murphy, Umberto Conte, Yiyun Tang, Sherry Wang, Keith D. Wilner, Liza C. Villaruz - Journal of Thoracic Oncology 2021 被引用: 168

  11. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

    著者: Benjamin Solomon, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Yiyun Tang, Keith D. Wilner, Fiona Blackhall, Tony Mok - Journal of Clinical Oncology 2018 被引用: 412

  12. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

    著者: Yi‐Long Wu, James Chih‐Hsin Yang, Dong‐Wan Kim, Shun Lü, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung‐Ju Ahn, Toshiaki Takahashi, Takeharu Yamanaka, Kemner Allison, Debasish Roychowdhury, Jolanda Paolini, Tiziana Usari, Keith D. Wilner, Kōichi Goto - Journal of Clinical Oncology 2018 被引用: 324

  13. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

    著者: Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Alka Chawla, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Kay Noonan, Yiyun Tang, M. Pastel, Keith D. Wilner, Yi‐Long Wu - Drugs 2020 被引用: 121

  14. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

    著者: Yaël P. Mossé, Stephan D. Voss, Megan S. Lim, Delphine Rolland, Charles G. Minard, Elizabeth Fox, Peter C. Adamson, Keith D. Wilner, Susan M. Blaney, Brenda J. Weigel - Journal of Clinical Oncology 2017 被引用: 403

  15. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

    著者: Yaël P. Mossé, Megan S. Lim, Stephan D. Voss, Keith D. Wilner, Katherine Ruffner, Julie Laliberté, Delphine Rolland, Frank M. Balis, John M. Maris, Brenda J. Weigel, Ashish M. Ingle, Charlotte H. Ahern, Peter C. Adamson, Susan M. Blaney - The Lancet Oncology 2013 被引用: 701

  16. Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

    著者: Mark M. Awad, Ryohei Katayama, Michele McTigue, Wei Liu, Ya-Li Deng, Alexei Brooun, Luc Friboulet, Donghui Huang, Matthew D. Falk, Sergei Timofeevski, Keith D. Wilner, Elizabeth L. Lockerman, Tahsin Khan, Sidra Mahmood, Justin F. Gainor, Subba R. Digumarthy, James R. Stone, Mari Mino–Kenudson, James G. Christensen, A. John Iafrate, Jeffrey A. Engelman, Alice T. Shaw - New England Journal of Medicine 2013 被引用: 413

  17. CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

    著者: Daniel B. Costa, Susumu Kobayashi, Shuchi S. Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D. Wilner - Journal of Clinical Oncology 2011 被引用: 590

  18. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

    著者: D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak, A. John Iafrate, Marileila Varella‐Garcia, Stephen B. Fox, Gregory J. Riely, Benjamin Solomon, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Ravi Salgia, P. Fidias, Jeffrey A. Engelman, Leena Gandhi, Pasi A. Jänne, Daniel B. Costa, Geoffrey I. Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith D. Wilner, Jeffrey W. Clark, Alice T. Shaw - The Lancet Oncology 2012 被引用: 1,277

  19. Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

    著者: James E. Butrynski, David R. D’Adamo, Jason L. Hornick, Paola Dal Cin, Cristina R. Antonescu, Suresh C. Jhanwar, Marc Ladanyi, Marzia Capelletti, Scott J. Rodig, Nikhil H. Ramaiya, Eunice L. Kwak, Jeffrey W. Clark, Keith D. Wilner, James G. Christensen, Pasi A. Jänne, Robert G. Maki, George D. Demetri, Geoffrey I. Shapiro - New England Journal of Medicine 2010 被引用: 867

  20. A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

    著者: Takaaki Sasaki, Jussi Koivunen, Atsuko Ogino, Masahiko Yanagita, Sarah Nikiforow, Wei Zheng, Christopher S. Lathan, Judith Marcoux, Jinyan Du, Katsuhiro Okuda, Marzia Capelletti, Takeshi Shimamura, Dalia Ercan, Magda Stumpfova, Yun Xiao, Stanislawa Weremowicz, Mohit Butaney, Stéphanie Héon, Keith D. Wilner, James G. Christensen, Michel J. Eck, Kwok‐Kin Wong, Neal I. Lindeman, Nathanael S. Gray, Scott J. Rodig, Pasi A. Jänne - Cancer Research 2011 被引用: 601

  21. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014

    著者: Benjamin Solomon, Federico Cappuzzo, Enriqueta Felip, Fiona Blackhall, Daniel B. Costa, Dong‐Wan Kim, Kazuhiko Nakagawa, Yi‐Long Wu, Tarek Mekhail, Jolanda Paolini, Jennifer Tursi, Tiziana Usari, Keith D. Wilner, Paulina Selaru, Tony Mok - Journal of Clinical Oncology 2016 被引用: 271

  22. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)

    著者: Jennifer H. Foster, Stephan D. Voss, David Hall, Charles G. Minard, Frank M. Balis, Keith D. Wilner, Stacey L. Berg, Elizabeth Fox, Peter C. Adamson, Susan M. Blaney, Brenda J. Weigel, Yaël P. Mossé - Clinical Cancer Research 2021 被引用: 115

  23. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group

    著者: Allison Magnuson, Suanna S. Bruinooge, Harpreet Singh, Keith D. Wilner, Shadia I. Jalal, Stuart M. Lichtman, Paul G. Kluetz, Gary H. Lyman, Heidi D. Klepin, Mark E. Fleury, Brad Hirsch, Allen S. Melemed, Fernanda I. Arnaldez, Upal Roy, Caroline Schenkel, Shimere Sherwood, Elizabeth Garrett‐Mayer - Clinical Cancer Research 2021 被引用: 88

  24. MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

    著者: Jochen K. Lennerz, Eunice L. Kwak, A. B. Ackerman, Michael Michael, Stephen B. Fox, Kristin Bergethon, Gregory Y. Lauwers, James G. Christensen, Keith D. Wilner, Daniel A. Haber, Ravi Salgia, Yung‐Jue Bang, Jeffrey W. Clark, Benjamin Solomon, A. John Iafrate - Journal of Clinical Oncology 2011 被引用: 430